Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | GAA | P10253 | 3/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30024728 | 1.00 | LMNA (0.69) | LMNAFFAR1KMT2AGAAALOX15 | |
| SCHEMBL413254 | 0.86 | LMNA (0.81) | LMNAFFAR1KMT2AALOX15MAPK1 | |
| SCHEMBL11128406 | 0.85 | KMT2A (0.62) | LMNAKMT2AGAAMAPK1MAPT | |
| SCHEMBL8976610 | 0.85 | KMT2A (0.62) | LMNAKMT2AGAAMAPK1MAPT | |
| SCHEMBL2719604 | 0.84 | KMT2A (0.60) | LMNAKMT2AGAAMAPK1MAPT | |
| SCHEMBL5532773 | 0.84 | KMT2A (0.60) | LMNAKMT2AGAAMAPK1MAPT | |
| SCHEMBL8948941 | 0.83 | KMT2A (0.61) | LMNAKMT2AGAAMAPK1MAPT | |
| SCHEMBL9320123 | 0.82 | KMT2A (0.59) | LMNAKMT2AGAAMAPK1MAPT | |
| SCHEMBL9911067 | 0.82 | GAA (0.72) | LMNAKMT2AGAAMAPK1MAPT | |
| SCHEMBL2777259 | 0.82 | L3MBTL1 (0.64) | LMNAKMT2AGAAMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115745457-A | High-adaptability concrete superplasticizer, preparation method and application thereof | 南京博特新材料有限公司 | 2023-03-07 | — | — | CN | claimed |
| CN-115725035-A | Slump-retaining concrete superplasticizer, preparation method and application thereof | 博特新材料泰州有限公司 | 2023-03-03 | — | — | CN | claimed |
| CN-105237561-A | Di-n-butyltin m-methyl phenoxy acetic ester and preparation method and application thereof | UNIV HENGYANG NORMAL | 2016-01-13 | — | — | CN | claimed |
| CN-102516196-A | Alpha, beta-unsaturated ketone compound containing thiazole heterocycle, its preparation method and application | UNIV SHANDONG | 2012-06-27 | — | — | CN | claimed |
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250115563-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2025-04-10 | — | — | US | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4356971-A2 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-3697421-B1 | LONGER-ACTING PROGESTIN PRODRUG CONTRACEPTIVES | EVESTRA INC (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117843968-A | Multifunctional solid concrete superplasticizer, preparation method and application | 江苏苏博特新材料股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-3704098-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| US-4598087-A | DIURETICS; ANALGESICS, PSYCHOTHERAPEUTICS | WARNER-LAMBERT COMPANY (US) | 1986-07-01 | — | — | US | disclosed |
| EP-0159864-A2 | Method of modifying taste | TATE & LYLE PUBLIC LIMITED COMPANY (GB) | 1985-10-30 | — | — | EP | disclosed |
| EP-0146297-A1 | Substituted trans-1,2-diaminocyclohexyl amide compounds | WARNER-LAMBERT COMPANY (US) | 1985-06-26 | — | — | EP | disclosed |
| EP-0104483-A2 | Sulfamoyl benzophenon derivatives, process for their preparation, their use, and pharmaceutical compositions based on these compounds | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-04-04 | — | — | EP | disclosed |
| US-4415494-A | BLUE-TO-BLACK COLORFAST DISPERSE, NITRO DYES; DIAZOTIZING A P-NITROANILINE AND COUPLING WITH AN N-SUBSTITUTED 1-NAPHTHYLAMINE | CASSELLA AKTIENGESELLSCHAFT (DE) | 1983-11-15 | — | — | US | disclosed |
| US-4314845-A | N4 -Phenoxyalkanoylsulfanilamides and herbicidal composition containing the same | SHIONOGI & CO., LTD. (JP) | 1982-02-09 | — | — | US | disclosed |
| EP-0036545-A1 | Water insoluble monoazo dyes, their preparation and their use | CASSELLA Aktiengesellschaft (DE) | 1981-09-30 | — | — | EP | disclosed |
| US-3985559-A | Toner powder for electrostatic images | OCE-VAN DER GRINTEN N.V. (NL) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | LMNA 3376/4885FFAR1 1632/4885KMT2A 4320/4885 |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | LMNA 3376/4885FFAR1 1632/4885KMT2A 4320/4885 |
| US-20250115563-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | LMNA 3376/4885FFAR1 1632/4885KMT2A 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.